KEYTRUDA® (pembrolizumab) - Official Site
WEBLearn about KEYTRUDA® (pembrolizumab), an immunotherapy that works with your immune system to help fight certain cancers. Visit the patient website.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as …
WEBDec 3, 2021 · Non-Small Cell Lung Cancer. KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and ... - Merck
WEB6 days ago · RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first-time presentation of overall survival (OS) results from the Phase 3 KEYNOTE-522 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single ...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEBNov 16, 2023 · Selected KEYTRUDA ® (pembrolizumab) Indications in the U.S. Gastric Cancer KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) …
WEB6 days ago · RAHWAY, N.J., September 15, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data from the pivotal Phase 3 KEYNOTE-006 ...
Pembrolizumab plus Chemotherapy in Advanced Endometrial …
WEBMar 27, 2023 · In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy...
FDA approves pembrolizumab as adjuvant treatment for non …
WEBOn January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a...
FDA approves pembrolizumab for adjuvant treatment
WEBOn November 17, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high...
Pembrolizumab plus Chemotherapy in Metastatic Non–Small …
WEBApr 16, 2018 · Pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, Bristol-Myers Squibb), and atezolizumab (Tecentriq, Genentech) are approved as second-line therapy.
Pembrolizumab for Early Triple-Negative Breast Cancer
WEBFeb 26, 2020 · Pembrolizumab (Keytruda, Merck Sharp & Dohme), an anti–programmed death 1 (PD-1) monoclonal antibody, has been shown to have antitumor activity and a range of mainly low-grade toxic effects in...
Skip to content